| 范玉霞,宋新志,吴小玲,李雨菲,张雪梅.不同anti-VEGF药物联合玻璃体切除术治疗增殖型糖尿病性视网膜病变效果及对视力水平的影响[J].现代生物医学进展英文版,2024,(3):537-541. |
| 不同anti-VEGF药物联合玻璃体切除术治疗增殖型糖尿病性视网膜病变效果及对视力水平的影响 |
| Effect of Different Anti-VEGF Drugs Combined with Vitrectomy on Proliferative Diabetic Retinopathy and Its Effect on Visual Acuity |
| Received:August 15, 2023 Revised:September 11, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.03.026 |
| 中文关键词: 雷珠单抗 康柏西普 阿柏西普 玻璃体切除术 PDR |
| 英文关键词: Ranibizumab Conbercept Aflibercept Vitrectomy PDR |
| 基金项目:甘肃省科技计划项目（22JR5RA675） |
|
| Hits: 378 |
| Download times: 313 |
| 中文摘要: |
| 摘要 目的：研究不同anti-VEGF药物联合玻璃体切除术治疗增殖型糖尿病性视网膜病变（PDR）效果及对视力水平的影响。方法：随机将2016年4月～2022年6月甘肃省人民医院收治的268例PDR患者分为雷珠单抗组（88例）、康柏西普组（90例）和阿柏西普组（90例），雷珠单抗组行雷珠单抗注射联合玻璃体切除术，康柏西普组行康柏西普注射联合玻璃体切除术，阿柏西普组行阿柏西普联合玻璃体切除术，观察三组患者的临床治疗效果，并检测其术前、术后7 d和28 d后的血管内皮细胞生长因子（VEGF）和促红细胞生长素（EPO）、最佳矫正视力（BCVA）、黄斑中心凹厚度（CMT）和眼压。结果：三组治疗总有效率比较，差异无统计学意义（P＞0.05）。康柏西普组、阿柏西普组治疗7 d后VEGF、EPO水平明显低于雷珠单抗组（P＜0.05）。康柏西普组、雷珠单抗组治疗7 d后BCVA水平明显低于阿柏西普组；康柏西普组、阿柏西普组治疗7 d后CMT水平低于雷珠单抗组（P＜0.05）。三组治疗前、治疗7 d后、治疗28 d后眼压比较，差异无统计学意义（P＞0.05）。结论：雷珠单抗、康柏西普、阿柏西普联合玻璃体切除术在PDR治疗中均具有较为显著的治疗效果，但康柏西普和阿柏西普在减少黄斑厚度方面效果更为显著，而雷珠单抗与康柏西普在改善视力方面效果更明显。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of different anti-VEGF drugs combined with vitrectomy on proliferative diabetic retinopathy (PDR) and its effect on visual acuity. Methods: A total of 268 patients with PDR admitted to Gansu Provincial People 's Hospital from April 2016 to June 2022 were randomly divided into ranibizumab group (88 cases), conbercept group (90 cases) and aflibercept group (90 cases). The ranibizumab group was treated with ranibizumab injection combined with vitrectomy, the conbercept group was treated with conbercept injection combined with vitrectomy, and the aflibercept group was treated with aflibercept combined with vitrectomy. The clinical effects of the three groups were observed. The levels of vascular endothelial growth factor (VEGF), erythropoietin (EPO), best corrected visual acuity (BCVA), central macular thickness (CMT) and intraocular pressure (IOP) were measured before operation, 7 days and 28 days after operation. Results: There was no difference in the total effective rate among the three groups (P>0.05). After 7 days of treatment, the levels of VEGF and EPO in the conbercept group and the aflibercept group were significantly lower than those in the ranibizumab group(P<0.05). The BCVA level in the conbercept group and the ranibizumab group was significantly lower than that in the aflibercept group after 7 days of treatment. The level of CMT in the conbercept group and the aflibercept group was lower than that in the ranibizumab group after 7 days of treatment(P<0.05). There was no significant difference in intraocular pressure between the three groups before treatment, 7 days after treatment and 28 days after treatment(P>0.05). Conclusion: Ranibizumab, conbercept and aflibercept combined with vitrectomy have significant therapeutic effects in the treatment of PDR, but conbercept and aflibercept are more effective in reducing macular thickness, while ranibizumab and conbercept are more effective in improving visual acuity. |
|
View Full Text
View/Add Comment Download reader |
| Close |
